Sitagliptin-Induced Acute Necrotizing Pancreatitis A Case Report

{"title":"Sitagliptin-Induced Acute Necrotizing Pancreatitis A Case Report","authors":"","doi":"10.47485/2767-5416.1064","DOIUrl":null,"url":null,"abstract":"Introduction: Sitagliptin is a dipeptidyl peptidase IV (DPP-IV) inhibitor used as an oral hypoglycemic agent in the treatment of type 2 Diabetes Mellitus. Acute pancreatitis is a rare known complication of sitagliptin, which can occur at any time after initiation of the drug therapy.\nCase Presentation: A 41 year-old female patient with type 2 diabetes mellitus presented with signs and symptoms of acute necrotizing pancreatitis. Recently, her GP added sitagliptin for more control on her disease. This drug induced acute pancreatitis. We admitted the patient to the ICU for monitoring after cessation of the causative agent. Fluid resuscitation and intravenous antibiotics were the definite treatment. Follow-up for three months showed no recurrence.\nClinical Discussion: Our patient had a fatal complication after the use of sitagliptin drug. Computed tomography scan with contrast is usually enough to reach the diagnosis. Early treatment is very important in these cases.\nConclusions: Sitagliptin is a good oral hypoglycemic agent to control glucose in patients with diabetes. Serious side effects should be monitored to avoid morbidity and mortality.","PeriodicalId":513191,"journal":{"name":"Journal of Medical Clinical Case Reports","volume":"20 29","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Medical Clinical Case Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.47485/2767-5416.1064","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Sitagliptin is a dipeptidyl peptidase IV (DPP-IV) inhibitor used as an oral hypoglycemic agent in the treatment of type 2 Diabetes Mellitus. Acute pancreatitis is a rare known complication of sitagliptin, which can occur at any time after initiation of the drug therapy. Case Presentation: A 41 year-old female patient with type 2 diabetes mellitus presented with signs and symptoms of acute necrotizing pancreatitis. Recently, her GP added sitagliptin for more control on her disease. This drug induced acute pancreatitis. We admitted the patient to the ICU for monitoring after cessation of the causative agent. Fluid resuscitation and intravenous antibiotics were the definite treatment. Follow-up for three months showed no recurrence. Clinical Discussion: Our patient had a fatal complication after the use of sitagliptin drug. Computed tomography scan with contrast is usually enough to reach the diagnosis. Early treatment is very important in these cases. Conclusions: Sitagliptin is a good oral hypoglycemic agent to control glucose in patients with diabetes. Serious side effects should be monitored to avoid morbidity and mortality.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
西他列汀诱发急性坏死性胰腺炎病例报告
简介西他列汀是一种二肽基肽酶IV(DPP-IV)抑制剂,是治疗2型糖尿病的口服降糖药。急性胰腺炎是西他列汀的一种罕见并发症,可在开始用药后的任何时间发生:一名 41 岁的 2 型糖尿病女性患者出现急性坏死性胰腺炎的症状和体征。最近,为了更好地控制病情,她的全科医生给她加用了西他列汀。这种药物诱发了急性胰腺炎。停用致病药物后,我们将患者送入重症监护室进行监护。液体复苏和静脉注射抗生素是明确的治疗方法。临床讨论:临床讨论:我们的患者在使用西格列汀药物后出现了致命的并发症。使用造影剂进行计算机断层扫描通常足以确诊。对于此类病例,早期治疗非常重要:西他列汀是控制糖尿病患者血糖的良好口服降糖药。应监测严重的副作用,以避免发病率和死亡率。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Mathematical and spatial epidemiology to rift valley fever and its association with climate in Sudan : Prospective study Reorganization of the Care Regulation Mechanism Intermediated By Health Technology Subsidies Effective Application of Biocompatible Magnetite Nanoparticles in the Treatment of Multiple Sclerosis: Results of a Clinical Study Case Report On Rare Co-Occurrence of Complicated Acute Appendicitis and Ovarian Cyst Rupture A First Reported Combination of Exon 18 Missense (G719X) Mutation and Exon 20 Insertion Mutation (Exon20ins) Of Epithelial Growth Factor Receptor in A Patient with Non-Small Cell Lung Carcinoma
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1